AUM Biosciences and Asymchem Complete Phase II API Production Campaign of Novel TRK Inhibitor

TEDA TIANJIN, P.R. China and SINGAPORE, Oct. 20, 2022 /PRNewswire/ -- Asymchem (stock code: 002821.SZ), a leading global contract development and manufacturing service provider, and AUM Biosciences (AUM), a global clinical stage biotech company, focused on discovering, acquiring and developing next generation targeted oncology therapeutics, jointly announced today the completion of their first GMP production campaign of AUM601.

Earlier this year, Asymchem and AUM Biosciences announced the two companies would collaborate on process development and clinical and commercial production of AUM 601, a highly selective oral small molecule inhibitor of the tropomyosin receptor kinase (TRK) for treating rare cancers.

The partnership resulted in 10 kg GMP bulk drug substance of AUM 601, which will be used to supply Phase II clinical trials. AUM 601 has shown potent in vitro and in vivo anti-tumor activities against tumors harboring NTRK fusion.

"Through our collaboration with Asymchem, we were able to develop a more robust manufacturing process for AUM 601 by utilizing affordable and safe reagents that enabled us to improve yield and quality. The promising data further justifies the advancement of AUM601 into Phase II clinical trials," said Vishal Doshi CEO, AUM Biosciences. "Asymchem surpassed our expectations and incorporated innovative ideas and development into the process, allowing us to further our work in transforming the oncology therapeutics market, and addressing unmet needs of patients."

The successful outcome of this collaboration is a testament to both Asymchem's and AUM's commitment to quality and excellence in drug development. "With Asymchem's world-class CDMO service and AUM's cutting-edge cancer research, together, we are poised to make a significant difference in the lives of cancer patients worldwide," added Elut Hsu, President of Asymchem, Inc.

Founded in 1999, Asymchem is a leading global integrated Contract Development and Manufacturing Organization (CDMO) providing innovative drug R&D and manufacturing. Asymchem is supported by 7000 employees based in PR China, the US, and the EU. Our mission is to drive efficiency through continuous technological advances for smarter, greener and more cost-effective manufacturing to support pharmaceutical clinical research and commercialization, backed by a proven track record of successful agency and industry inspections. For more information, please visit www.asymchem.com.

AUM Biosciences is a global clinical stage biotech company, focused on discovering and developing novel targeted oncology therapies, particularly for cancers with a clear genetic marker. The management team has an extensive track record of selecting distinctive early-stage assets, successfully exiting virtual biotech models, and has contributed significantly to the development of several currently marketed oncology treatments with annual peak sales up to $3B. AUM was founded to enable a holistic strategy for drug development and improving the probability of success with a focus on synergism, sustainability, and scalability. To know more, visit www.aumbiosciences.com

This press release contains projections and other forward-looking statements regarding future events or our future financial performance. All statements other than present and historical facts and conditions contained in this release, including any statements regarding our future results of operations and financial positions, business strategy, plans and our objectives for future operations, are forward-looking statements. Actual results or developments may vary, depending on changes in the operating environment. Neither Asymchem nor its subsidiaries assume an obligation to update the forecasts, expectations or statements contained in this release.

SOURCE Asymchem